Put companies on watchlist
Newron Pharmaceuticals S.p.A.
ISIN: IT0004147952
WKN: A0LF18
Curious about what AI knows about Newron Pharmaceuticals? Just one click more
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Newron Pharmaceuticals S.p.A. · ISIN: IT0004147952 · EQS - adhoc news (68 News)
Country: Italy · Primary market: Italy · EQS NID: 1882643
17 April 2024 11:38AM

Newron vermeldet die Resultate der Generalversammlung 2024


EQS-Ad-hoc: Newron Pharmaceuticals S.p.A. / Schlagwort(e): Hauptversammlung
Newron vermeldet die Resultate der Generalversammlung 2024

17.04.2024 / 11:38 CET/CEST
Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014, übermittelt durch EQS News - ein Service der EQS Group AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.


Newron vermeldet die Resultate der Generalversammlung 2024

Mailand, Italien, 17. April 2024, [11.30 Uhr MESZ] – Newron Pharmaceuticals S.p.A. (ISIN: IT0004147952, SIX: NWRN, XETRA: NP5) gibt bekannt, dass seine Aktionärinnen und Aktionäre allen Anträgen der Tagesordnung des ordentlichen Teils der heute abgehaltenen Generalversammlung 2024 zugestimmt haben. Die Anträge der Tagesordnung des außerordentlichen Teils der Versammlung wurden nicht zur Abstimmung gestellt, da das erforderliche Quorum nicht erreicht wurde.

- Ende der Insiderinformation -

Für weitere Informationen:

Newron

Stefan Weber – CEO, +39 02 6103 46 26, pr@newron.com

 

 



Ende der Insiderinformation

17.04.2024 CET/CEST Die EQS Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter https://eqs-news.com


1882643  17.04.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1882643&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Newron Pharmaceuticals S.p.A.
Smart analysis and research tools can be found here.
MIC: XSWX
Power-Shortcuts

Newron Pharmaceuticals SpA

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.